Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications?

In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. https://t.co/lMaUXWNwLB

This article argues that Hatch-Waxman properly applies utilitarian principles to issues of biopharmaceutical development by balancing innovation and availability, but that the statute’s efficacy has been marred by "pay-for-delay" arrangements. https://t.co

RT @GWHPM950: As policymakers and the judicial branch consider solutions for prescription drugs, "the greatest good for the greatest number…

RT @GWHPM950: As policymakers and the judicial branch consider solutions for prescription drugs, "the greatest good for the greatest number…